Daiichi Sankyo in Talks with AstraZeneca for the Supply of AZD1222 to Combat COVID-19 in Japan

Daiichi Sankyo in Talks with AstraZeneca for the Supply of AZD1222 to Combat COVID-19 in Japan

Shots:

  • Following the AstraZeneca’s discussion with the Japanese government to introduce COVID-19 vaccine in Japan, Daiichi Sankyo has advanced its conversation with AstraZeneca to formulate the vaccine, including vial filling, packaging, and storage
  • Daiichi Sankyo plans to receive Oxford’s undiluted vaccine, which it will finish at its own facilities. The collaboration allows AstraZeneca to reach its goal of producing 2B doses/year
  • Additionally, Daiichi Sankyo will continue its ongoing research and development of an inhaled formulation of anticoagulant Nafamostata & will advance its mRNA vaccine candidate, co-developed with the University of Tokyo

Click here to read full press release/ article | Ref: Daiichi Sankyo | Image: Pharmashots

Related News: AstraZeneca Signs an Agreement with Symbiosis for Sterile Manufacturing of its AZD1222 Against COVID-19